Trial Profile
An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non Neutropenic Patients With Candidemia, With or Without Invasive Candidiasis, Inclusive of Patients With Suspected Resistance to Standard of Care Antifungal Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Fosmanogepix (Primary) ; Fosmanogepix (Primary)
- Indications Candidaemia
- Focus Proof of concept; Therapeutic Use
- Sponsors Pfizer
- 19 Aug 2023 Results published in the Journal of Antimicrobial Chemotherapy.
- 25 Oct 2020 Results presented at the IDWeek 2020
- 25 Oct 2020 Results of a subset analysis assessing outcomes in patients with varying degrees of renal insufficiency presented at the IDWeek 2020